Table 2.

Vaccine efficacy parameters and assumptions

Gender	Male				Female
HPV genotype	6	11	16	18	6	11	16	18
Against transient infection†,‡
- Cervical, vaginal & vulvar diseases	―	―	41.1	62.1	―	―	76.0	96.3
- Genital warts & HPV 6, 11	49.0	57.0	―	―	76.1	76.1	―	―
Against persistent infection
- Anal disease	―	―	78.7	96.0	―	―	98.8	98.4
- Cervical, vaginal & vulvar diseases	―	―	―	―	―	―	98.8	98.4
- Penile disease	―	―	78.7	96.0	―	―	―	―
Against individual diseases
- Genital warts	84.3	90.9	―	―	98.9	100.0	―	―

Unit: percentage. Values were derived from [17].

^†Efficacy against genital infection in males is assumed to prevent transmission of genital infection to females, and vice versa.

^‡Efficacy for 1 and 2 doses assumed to be 23% and 45% of efficacy of the full 3 doses, respectively.

*Efficacy against anal, head and neck, penile cancers is conferred through protection against infection only.